Skip to main
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

uniQure NV demonstrates a promising outlook due to its strategic advancements in gene therapies, particularly with AMT-130 and AMT-191, which have gained credibility through recent updates and data from the WORLD 2026 conference. The increase in SG&A expenses to $21.6 million, up from $11.4 million year-over-year, reflects the company's commitment to bolster its clinical and operational capabilities as it prepares for potential product launches. Furthermore, the company’s robust pipeline addressing multiple genetic conditions and the adaptability of its balance sheet are seen as supporting factors that enhance investor confidence and indicate significant upside potential for uniQure’s stock.

Bears say

uniQure NV faces significant challenges due to intense market competition from both existing and emerging therapies that may hinder its ability to penetrate the market effectively and impact pricing strategies. As a clinical stage company, uniQure has yet to bring a revenue-generating product to market and has reported ongoing losses since its inception, indicating serious financial risks. Furthermore, potential delays in clinical development, regulatory approvals, or commercialization timelines could lead to prolonged development periods and increased costs, exacerbating the company's financial instability.

uniQure (QURE) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 11 analysts, uniQure (QURE) has a Buy consensus rating as of Apr 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.